SERES
For 36 years, SERES, a subsidiary of the eponymous Chinese group, has positioned itself as a premium smart e-vehicle brand. After five years of development and testing, the company is officially launching the cutting-edge, high-performing, high-tech SERES 5 in Europe. Available in three models (Standard version 2WD, Premium version 4WD, Flagship version 4WD) the SERES 5 is a sporty, premium e-SUV that blazes a new trail by combining the best of everything: design, smart driving, power, range and comfort. From January 14 to 22, visitors to the Brussels Motor Show will get an exclusive sneak peek at the premium sport E-SUV before it goes on sale in March.
Natural Aesthetics of Life
Many people sat up and took notice when the SERES 5 concept was unveiled in Silicon Valley. In particular, its design caught their eye as SERES5 is inspired by nature with flexibility, purity and vitality. Special attention was paid to the nature-inspired aesthetics (Σ front face, willow-inspired window, Belt line mimics dolphin’s leaping). The roofline continuously and uninterruptedly descends to the trunk, giving the vehicle an ultra-low wind resistance, making it more dynamic and more energy efficient 1. The SERES 5 is available in 8 exterior colours and 5 interior ones that can be combined as desired.
Zero to 100 km/h in 3.7 seconds and a range up to 530 km
Behind its premium design lies an amazing driving experience enhanced by a performance worthy of the market’s top models. The SERES 5 accelerates from 0 to 100 km/h in 3.7 seconds thanks to its front and rear motor peak power (430KW) and peak torque 960N.m.
To control acceleration and stabilize the vehicle, the chassis is mainly made of a strong, lightweight aluminium alloy. For a premium driving experience, a dual ball joint front double-wishbone front suspension enhances anti-roll performance and a multi-link trapezoidal arm type rear independent suspension improves stability.
The SERES 5 boasts an outstanding range. Its 80kWh lithium iron phosphate and 90 kWh semi solid state high performance batteries offer a significant power supply and high energy efficiency. Thus, on a single charge the 2WD model can travel 500 km WLTP and the 4WD can cover 530 km WLTP. They are compatible with 95% of the charging systems available in Europe. Moreover, SERES 5 includes a smart fast charging system: a quick recharge to shorten the waiting time on the way and, on camping ground, a V2L function can provide power to many travel appliances such as induction cookers and coffee makers, while the V2V function can also help charge other people’s EV’s in emergency.
The SUV is also equipped with an industry leading permanent magnet motor: a little technological gem.
A safe, unparalleled driving experience
The SERES 5 also stands out for its 18 assisted-driving features, +300 smart voice assistants (8 active service reminders, 14 telephone operations, 17 navigation operations, 35 multimedia operations, ...), 3 smart scenarios (rest mode, temporary stop mode, camping mode) and over 20 "Smart Car Ecology" devices (on-line map, On-line music, car game, DAB digital radio).
As a safety feature, voice commands let the driver control everything from air conditioning to music while keeping both hands on the wheel and eyes on the road. The SERES 5 also has LFP batteries and, for the first time, a semi-solid battery as standard equipment that has undergone around 100 tests, with a long service life (100,000 km without degradation) and high peak power (430 KW). What’s more, the SERES 5 benefits from a five-level safety management system and has travelled the equivalent of 5.000.000 km in extreme conditions (cold, heat, high altitudes, etc.) to ensure optimal use. To provide the best of breed, the brand has also gathered a global supply chain system of experts (Astemo, Longhorn, Bosch, Valeo, Pirelli, BASF, …) around its SERES 5.
Finally in order to provide worry-free travel to its customers, SERES offers two outstanding warrantees: a 8 years (160.000 km) warranty for the battery, electric motor and electric control system and a 4 years (100.000 km) warranty for the vehicle. Besides, SERES 5 drivers will benefit from a 24hours emergency rescue road service, as well as online and offline customer services to all SERES valued customer.
Custom-made comfort for stress-free driving
SERES takes pride in putting technology to work for drivers and passengers with intelligent interiors geared to their needs. For example, instead of displaying all the features on a single central screen, three of them are arrayed around the driver to make the important messages visible while ensuring that the view is clear at every angle (HUD, 15.6” large central control screen, 12.3” LCD dashboard).
For a comfortable ride, the front seat can be adjusted in 12 different ways and is equipped with various settings such as ventilation, heating, memory, massage ... The SERES 5 also has two 40W wireless fast chargers (front and rear) to meet a wide variety of needs. The optional 85-inch deluxe panoramic skyline (field ratio 97.7%) offers a wide range of view while giving a unique impression of space. Lastly, new soundproofing and heat insulation materials keep the inside very quiet whatever the speed.
At the press conference, Mr. John Zhang, the chairman and founder of SERES Group emphasized that “In making SERES into a high-end, intelligent new energy vehicle brand, starting 2016, the group had consistently invested over 10% of its total revenue each year in Intelligent EV technologies. We have built industry 4.0 standard Intelligent factories, have developed and launched high-performance battery and range of other intelligent EV related products. Today these technologies are not only leading the sector in China but are considered to be on an advanced level on a global scale.”
The SERES 5 will be available from the brand's European sales network in March
Dimensions: 4710 x 1930 x 1620 mm
Standard version 2WD: from €63,9002
Premium version 4WD: from €67,900
Flagship version 4WD: from €74,900
1278 Cd drag coefficient
2 indicative prices for the German market
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom